• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

聚乙二醇脂质解吸率对 siRNA 脂质纳米粒的药代动力学和药效学的影响。

Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles.

机构信息

Acuitas Therapeutics, Vancouver, British Columbia, Canada.

Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.

出版信息

Mol Ther Nucleic Acids. 2013 Dec 17;2(12):e139. doi: 10.1038/mtna.2013.66.

DOI:10.1038/mtna.2013.66
PMID:24345865
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3894582/
Abstract

Lipid nanoparticles (LNPs) encapsulating short interfering RNAs that target hepatic genes are advancing through clinical trials, and early results indicate the excellent gene silencing observed in rodents and nonhuman primates also translates to humans. This success has motivated research to identify ways to further advance this delivery platform. Here, we characterize the polyethylene glycol lipid (PEG-lipid) components, which are required to control the self-assembly process during formation of lipid particles, but can negatively affect delivery to hepatocytes and hepatic gene silencing in vivo. The rate of transfer from LNPs to plasma lipoproteins in vivo is measured for three PEG-lipids with dialkyl chains 14, 16, and 18 carbons long. We show that 1.5 mol % PEG-lipid represents a threshold concentration at which the chain length exerts a minimal effect on hepatic gene silencing but can still modify LNPs pharmacokinetics and biodistribution. Increasing the concentration to 2.5 and 3.5 mol % substantially compromises hepatocyte gene knockdown for PEG-lipids with distearyl (C18) chains but has little impact for shorter dimyristyl (C14) chains. These data are discussed with respect to RNA delivery and the different rates at which the steric barrier disassociates from LNPs in vivo.Molecular Therapy-Nucleic Acids (2013) 2, e139; doi:10.1038/mtna.2013.66; published online 17 December 2013.

摘要

脂质纳米颗粒(LNPs)将靶向肝脏基因的短干扰 RNA 包裹在内,正在临床试验中取得进展,早期结果表明,在啮齿动物和非人类灵长类动物中观察到的出色基因沉默也适用于人类。这一成功促使研究人员寻找进一步推进这一递送平台的方法。在这里,我们对聚乙二醇脂质(PEG-脂质)成分进行了表征,这些成分是控制脂质颗粒形成过程中自组装的必需条件,但会对向肝细胞的递送和体内肝脏基因沉默产生负面影响。我们测量了三种具有 14、16 和 18 个碳原子长的二烷基链的 PEG-脂质在体内从 LNPs 向血浆脂蛋白转移的速率。我们表明,1.5mol%的 PEG-脂质代表一个阈值浓度,在此浓度下,链长对肝脏基因沉默的影响最小,但仍可以改变 LNPs 的药代动力学和生物分布。将浓度增加到 2.5%和 3.5%会大大降低具有二硬脂酰基(C18)链的 PEG-脂质对肝细胞基因敲低的效果,但对较短的二肉豆蔻酰基(C14)链的影响很小。这些数据与 RNA 递送以及体内立体障碍与 LNPs 分离的不同速率有关。分子治疗-核酸(2013 年)2,e139;doi:10.1038/mtna.2013.66;在线发布于 2013 年 12 月 17 日。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16c2/3894582/b7b341e1456b/mtna201366f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16c2/3894582/be6b334762c1/mtna201366f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16c2/3894582/2d5aec9749e2/mtna201366f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16c2/3894582/49c20d2342e2/mtna201366f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16c2/3894582/1f58e0218a5c/mtna201366f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16c2/3894582/b7b341e1456b/mtna201366f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16c2/3894582/be6b334762c1/mtna201366f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16c2/3894582/2d5aec9749e2/mtna201366f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16c2/3894582/49c20d2342e2/mtna201366f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16c2/3894582/1f58e0218a5c/mtna201366f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16c2/3894582/b7b341e1456b/mtna201366f5.jpg

相似文献

1
Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles.聚乙二醇脂质解吸率对 siRNA 脂质纳米粒的药代动力学和药效学的影响。
Mol Ther Nucleic Acids. 2013 Dec 17;2(12):e139. doi: 10.1038/mtna.2013.66.
2
Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method.聚乙二醇锚定物和血清对脂质纳米颗粒的影响:一种纳米颗粒追踪方法的开发
Pharmaceutics. 2023 Feb 10;15(2):597. doi: 10.3390/pharmaceutics15020597.
3
Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.通过脂质纳米颗粒平台对小干扰RNA肝脏递送的生理和生化屏障进行定量分析。
Mol Pharm. 2014 May 5;11(5):1424-34. doi: 10.1021/mp400584h. Epub 2014 Apr 1.
4
Effect of PEGylation on biodistribution and gene silencing of siRNA/lipid nanoparticle complexes.聚乙二醇化对 siRNA/脂质纳米粒复合物的生物分布和基因沉默的影响。
Pharm Res. 2013 Feb;30(2):342-51. doi: 10.1007/s11095-012-0874-6. Epub 2012 Sep 15.
5
PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM production.聚乙二醇(PEG)化脂质纳米颗粒在小鼠体内的血清除率依赖于 PEG 脱落率:PEG 脱落越快,抗-PEG IgM 产生越少。
Int J Pharm. 2020 Oct 15;588:119792. doi: 10.1016/j.ijpharm.2020.119792. Epub 2020 Aug 19.
6
pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.载有 siRNA 的脂质纳米粒的 pH 敏感性聚乙二醇化可改善其在肝细胞中的主动靶向和基因沉默活性。
J Control Release. 2017 Sep 28;262:239-246. doi: 10.1016/j.jconrel.2017.07.046. Epub 2017 Aug 1.
7
siRNA delivery to lymphatic endothelial cells via ApoE-mediated uptake by lipid nanoparticles.通过载脂蛋白E介导脂质纳米颗粒摄取将小干扰RNA递送至淋巴管内皮细胞。
J Control Release. 2023 Jan;353:125-133. doi: 10.1016/j.jconrel.2022.11.036. Epub 2022 Nov 23.
8
Hydrophobic scaffolds of pH-sensitive cationic lipids contribute to miscibility with phospholipids and improve the efficiency of delivering short interfering RNA by small-sized lipid nanoparticles.具有 pH 敏感性的阳离子脂质的疏水支架有助于与磷脂混合,并通过小尺寸脂质纳米颗粒提高短干扰 RNA 的递送效率。
Acta Biomater. 2020 Jan 15;102:341-350. doi: 10.1016/j.actbio.2019.11.022. Epub 2019 Nov 13.
9
Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.皮下给药后用于肝细胞基因沉默的 siRNA 的脂质纳米粒制剂的开发。
J Control Release. 2014 Dec 28;196:106-12. doi: 10.1016/j.jconrel.2014.09.025. Epub 2014 Oct 5.
10
Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform.采用微流控混合平台制备和表征用于基因传递的脂质纳米粒。
J Vis Exp. 2021 Feb 25(168). doi: 10.3791/62226.

引用本文的文献

1
Bioinspired Extracellular Vesicles for Enhanced Delivery of siRNA to Tumors.用于增强小干扰RNA向肿瘤递送的仿生细胞外囊泡
Methods Mol Biol. 2025;2965:377-401. doi: 10.1007/978-1-0716-4742-4_19.
2
Formulation-Driven Optimization of PEG-Lipid Content in Lipid Nanoparticles for Enhanced mRNA Delivery In Vitro and In Vivo.脂质纳米颗粒中聚乙二醇脂质含量的配方驱动优化以增强mRNA在体外和体内的递送
Pharmaceutics. 2025 Jul 22;17(8):950. doi: 10.3390/pharmaceutics17080950.
3
Viral and nonviral nanocarriers for CRISPR-based gene editing.用于基于CRISPR的基因编辑的病毒和非病毒纳米载体。

本文引用的文献

1
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.在健康志愿者中,一种 RNA 干扰药物对前蛋白转化酶枯草溶菌素/柯萨奇蛋白酶 9(PCSK9)合成和血清 LDL 胆固醇浓度的影响:一项随机、单盲、安慰剂对照、1 期临床试验。
Lancet. 2014 Jan 4;383(9911):60-68. doi: 10.1016/S0140-6736(13)61914-5. Epub 2013 Oct 3.
2
Safety and efficacy of RNAi therapy for transthyretin amyloidosis.RNAi 疗法治疗转甲状腺素淀粉样变性的安全性和有效性。
N Engl J Med. 2013 Aug 29;369(9):819-29. doi: 10.1056/NEJMoa1208760.
3
Nano Res. 2024 Oct;17(10):8904-8925. doi: 10.1007/s12274-024-6748-5. Epub 2024 Jun 20.
4
Low-liver-accumulation lipid nanoparticles enhance the efficacy and safety of HPV therapeutic tumor vaccines.低肝脏蓄积脂质纳米颗粒增强HPV治疗性肿瘤疫苗的疗效和安全性。
J Transl Med. 2025 Aug 11;23(1):893. doi: 10.1186/s12967-025-06924-2.
5
Positron Emission Tomography-Based Pharmacokinetics of mRNA-Lipid Nanoparticles: A Study Quantifying the ApoE and Macrophage Contribution.基于正电子发射断层扫描的mRNA-脂质纳米颗粒药代动力学:一项量化载脂蛋白E和巨噬细胞贡献的研究。
ACS Appl Mater Interfaces. 2025 Aug 13;17(32):45625-45639. doi: 10.1021/acsami.5c14143. Epub 2025 Aug 3.
6
Modulating Immunogenicity and Reactogenicity in mRNA-Lipid Nanoparticle Vaccines through Lipid Component Optimization.通过脂质成分优化调节mRNA-脂质纳米颗粒疫苗的免疫原性和反应原性
ACS Nano. 2025 Aug 5;19(30):27977-28001. doi: 10.1021/acsnano.5c10648. Epub 2025 Jul 23.
7
Rational design of lipid nanoparticles for enabling gene therapies.用于实现基因治疗的脂质纳米颗粒的合理设计。
Mol Ther Methods Clin Dev. 2025 Jun 18;33(3):101518. doi: 10.1016/j.omtm.2025.101518. eCollection 2025 Sep 11.
8
Eliciting antitumor immunity via therapeutic cancer vaccines.通过治疗性癌症疫苗激发抗肿瘤免疫力。
Cell Mol Immunol. 2025 Jul 9. doi: 10.1038/s41423-025-01316-4.
9
Lipid nanoparticle screening in nonhuman primates with minimal loss of life.在非人灵长类动物中进行脂质纳米颗粒筛选,同时将生命损失降至最低。
Nat Biotechnol. 2025 Jun 26. doi: 10.1038/s41587-025-02711-y.
10
Inhaled non-viral delivery systems for RNA therapeutics.用于RNA治疗的吸入式非病毒递送系统。
Acta Pharm Sin B. 2025 May;15(5):2402-2430. doi: 10.1016/j.apsb.2025.03.033. Epub 2025 Mar 19.
Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics.
可生物降解脂质使 RNAi 治疗药物的全身递送系统能够快速消除脂质纳米颗粒。
Mol Ther. 2013 Aug;21(8):1570-8. doi: 10.1038/mt.2013.124. Epub 2013 Jun 25.
4
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.在有肝脏受累的癌症患者中,针对 VEGF 和 KSP 的 RNA 干扰治疗药物的首次人体试验。
Cancer Discov. 2013 Apr;3(4):406-17. doi: 10.1158/2159-8290.CD-12-0429. Epub 2013 Jan 28.
5
Liposomal drug delivery systems: from concept to clinical applications.脂质体药物递送系统:从概念到临床应用。
Adv Drug Deliv Rev. 2013 Jan;65(1):36-48. doi: 10.1016/j.addr.2012.09.037. Epub 2012 Oct 1.
6
Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core.通过微流体混合合成的含小干扰RNA的脂质纳米颗粒呈现出电子致密的纳米结构核心。
J Phys Chem C Nanomater Interfaces. 2012 Aug 30;116(34):18440-18450. doi: 10.1021/jp303267y. Epub 2012 Jul 18.
7
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.最大限度地提高 siRNA 脂质纳米粒在体内肝脏基因沉默中的效力。
Angew Chem Int Ed Engl. 2012 Aug 20;51(34):8529-33. doi: 10.1002/anie.201203263. Epub 2012 Jul 10.
8
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.基于内源性和外源性配体的靶向 RNAi 治疗药物递送。
Mol Ther. 2010 Jul;18(7):1357-64. doi: 10.1038/mt.2010.85. Epub 2010 May 11.
9
Rational design of cationic lipids for siRNA delivery.阳离子脂质体的 siRNA 递呈的合理设计。
Nat Biotechnol. 2010 Feb;28(2):172-6. doi: 10.1038/nbt.1602. Epub 2010 Jan 17.
10
Development of lipidoid-siRNA formulations for systemic delivery to the liver.用于全身递送至肝脏的脂质体-siRNA制剂的研发。
Mol Ther. 2009 May;17(5):872-9. doi: 10.1038/mt.2009.36. Epub 2009 Mar 3.